Literature DB >> 7198384

Estrogen receptors in the human female lower uninary tract.

C S Iosif, S Batra, A Ek, B Astedt.   

Abstract

Cytosolic and nuclear fractions prepared from the urethra, urinary bladder, and trigonum of the bladder obtained at urethrocystectomy from four female patients were analyzed for the presence of estrogen receptors. High-affinity estradiol receptors (KD 0.7 x 10(-9)M) could be detected in both cytosolic and nuclear fractions of the urethra from all four patients. Estradiol receptors could be detected in only the nuclear fractions of the urinary bladder in two of the four preparations. In the trigonum, cytosolic and nuclear receptors could be measured in one and three preparations, respectively. The receptor concentrations in both trigonum and the bladder were lower than those in the urethra. By providing experimental evidence for the presence of estradiol receptors in the lower uninary tract, the present data advance the case for estradiol therapy in incontinent patients.

Entities:  

Keywords:  Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Endocrine System; Estradiol; Estrogens; Family Planning; Genitalia; Genitalia, Female; Hormones; Ingredients And Chemicals; Organic Chemicals; Physiology; Progestational Hormones; Progesterone; Urogenital System; Uterine Effects; Uterus

Mesh:

Substances:

Year:  1981        PMID: 7198384     DOI: 10.1016/0002-9378(81)90710-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  53 in total

1.  Effects of tamoxifen on Doppler velocimetry parameters of periurethral vessels in postmenopausal women.

Authors:  Carlos A Faria; Marair G F Sartori; Edmund C Baracat; Geraldo Rodrigues de Lima; Manoel J B C Girão
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2004-08-25

2.  Long-term observation of the detrusor smooth muscle in rats. Its relationship to ovariectomy and estrogen treatment.

Authors:  B Eika; L N Salling; L L Christensen; A Andersen; S Laurberg; C C Danielsen
Journal:  Urol Res       Date:  1990

3.  Direct effect of amezinium on rabbit urethra: effect of estrogen and progesterone treatment.

Authors:  M Ishigooka; T Hashimoto; Y Suzuki; O Ichiyanagi; I Sasagawa; T Nakada
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1996

Review 4.  Urinary symptoms in breast cancer: a systematic review.

Authors:  Kristine A Donovan; Alice R Boyington; Roohi Ismail-Khan; Jean F Wyman
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

5.  Hormone replacement therapy has no routine role in the management of postmenopausal voiding dysfunction.

Authors:  Lesley K Carr
Journal:  Can Urol Assoc J       Date:  2009-04       Impact factor: 1.862

6.  Immunohistochemical analysis of estrogen receptors in the urethra of sexually intact, ovariectomized, and estrogen-substituted ovariectomized sheep.

Authors:  Heinz R Augsburger; Constanze Führer
Journal:  Int Urogynecol J       Date:  2013-12-07       Impact factor: 2.894

7.  Bladder cancer and reproductive factors among women in Spain.

Authors:  An-Tsun Huang; Manolis Kogevinas; Debra T Silverman; Nuria Malats; Nathaniel Rothman; Adonina Tardón; Consol Serra; Reina García-Closas; Alfredo Carrato; Kenneth P Cantor
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

Review 8.  Role of oestrogen receptors in bladder cancer development.

Authors:  Iawen Hsu; Spencer Vitkus; Jun Da; Shuyuan Yeh
Journal:  Nat Rev Urol       Date:  2013-04-16       Impact factor: 14.432

9.  Hysterectomy associated with de novo lower urinary tract symptoms in a Taiwanese population: a nationwide, population-based study.

Authors:  Pei-Chen Li; Huei-Kai Huang; Dah-Ching Ding
Journal:  Int Urogynecol J       Date:  2018-10-24       Impact factor: 2.894

10.  Enhancement of Escherichia coli adherence to epithelial cells derived from estrogen-stimulated rats.

Authors:  J D Sobel; D Kaye
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.